Harnessing glycan-modified antigens, AmbroSia Therapeutics aims to modulate immune responses. Their technology has potential applications in a wide variety of auto-immune diseases, oncology and infectious diseases. The initial focus is on the development of an immune modulating therapeutic for Type 1 Diabetes, for which preclinical proof-of-concept has been shown.